Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 31, 2020

SELL
$2.25 - $5.8 $929 - $2,395
-413 Closed
0 $0
Q3 2019

Oct 25, 2019

SELL
$2.22 - $3.39 $677 - $1,033
-305 Reduced 42.48%
413 $1,000
Q2 2019

Aug 02, 2019

BUY
$1.8 - $3.3 $1,292 - $2,369
718 New
718 $2,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Tarbox Family Office, Inc. Portfolio

Follow Tarbox Family Office, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tarbox Family Office, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Tarbox Family Office, Inc. with notifications on news.